Articles tagged with Drug Therapy
A phase 2 clinical trial found that burosumab safely restored normal phosphate levels and improved physical function in patients with severe fibrous dysplasia. Key findings include reduced pain, fatigue, and mobility impairment, as well as significant improvements in children's mobility and independence.
Researchers used wastewater surveillance to detect drug-resistant Candida auris strains up to five months before patients showed symptoms, opening a new frontier for hospitals. The study found higher detection rates and concentrations of the pathogen in hospital wastewater compared to community-scale treatment plants.
A USC-led study analyzed insurance claims data from 940 patients with ALK-positive non-small cell lung cancer to compare the effectiveness of five tyrosine kinase inhibitors. The results showed alectinib and lorlatinib as promising treatments, offering longer survival times and better treatment duration compared to other options.
A new study presents dual immunization against respiratory syncytial virus (RSV) using RSVpreF and nirsevimab, showing reduced hospitalizations among infants in France. The study found that this combined approach demonstrates potential for enhanced RSV prevention and protection
A novel antibody, NG101, accelerates the regeneration of damaged spinal cord tissue by neutralizing a protein that blocks nerve fiber growth. This therapy enables new nerve fibers to form functional connections, allowing patients to become more independent and potentially recover arm and hand function.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Regular physical activity is essential for mitigating the regain of lost weight after discontinuing GLP-1 medications. Exercise has complementary effects beyond energy balance, including improved insulin sensitivity and increased fat oxidation. Clinicians must develop individualized strategies to improve exercise adherence.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A new study from Karolinska Institutet shows that low doses of endoxifen reduce breast density to the same extent as tamoxifen without causing severe side effects. The results suggest a lower dose may be sufficient for therapeutic effect while being better tolerated.
A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
A new study shows that while dental opioid prescription fills in the US have dropped by 27% since 2021, the rate remains higher than in other developed countries and the US territory of Puerto Rico. The study suggests that some US dentists are still overprescribing opioids.
A recent study from the University of Eastern Finland found that people with Parkinson's disease are using psychotropics more frequently than controls, even before diagnosis. The use of psychotropic medications increases as the disease progresses, reflecting emerging non-motor symptoms and worsening disease progression.
A new analysis found that prescriptions for curable hepatitis C drugs have declined sharply in recent years, leaving millions without treatment. The researchers urge swift actions to deliver the drugs to those who need them, including increased screening and system-level changes.
A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers identified patient-reported symptoms associated with GLP-1s, including menstrual changes, fatigue, and temperature-related complaints, that may not be fully captured in clinical trials or drug labeling. Nearly 4% of Reddit users reported reproductive symptoms, and fatigue was the second most common complaint.
Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
A new analysis from UC San Francisco argues that diagnostics are being overlooked, slowing progress against major diseases despite advances in targeted therapies. The study suggests that nearly half of the world's population lacks adequate access to diagnostics due to inadequate investment and insurance reimbursement.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
City St George's, University of London, is partnering with Paradigm Biopharmaceuticals to test a potential treatment for osteoarthritis. The partnership aims to investigate the mechanism of action of pentosan polysulfate sodium (iPPS) on bone marrow lesions, which are linked to pain in osteoarthritis.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
Researchers identified NOX-1 as a key molecular target to prolong ketamine's therapeutic benefits. Combining ketamine with NOX-1 inhibitors significantly extended its antidepressant-like effects. K-4, a novel AMPAR modulator, also showed rapid antidepressant effects that persisted for at least 2 weeks.
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
Researchers have identified and overcome metabolic instability as the key barrier to developing ovalicin, a potent relative of fumagillin. Using chem-bio hybrid synthesis, they created metabolically stable drug candidates that worked in animal models of amebiasis.
A Concordia-led study reveals that many Canadian surgery residents scored below the threshold of adequate pain knowledge, with limited grasp of the biopsychosocial model and unpreparedness to treat pain in children. This highlights the need for improved medical training to address this critical gap.
A study found that cancer patients during the last phase of life experienced more bleeding events than thromboembolic events. Most patients continued their antithrombotic therapy despite increased bleeding risk, with over 28% experiencing at least one bleeding episode.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Research reveals associations between antiseizure drugs and neurodevelopmental disorders in children, with valproate and zonisamide linked to increased risks. The study highlights the need for continued monitoring of new antiseizure drugs and further evaluation of their safety during pregnancy.
Research shows that bacteria harbor resistance genes may respond differently to antibiotics under non-standard conditions. This affects treatment efficacy and contributes to understanding antimicrobial resistance development and spread. Understanding these variations is crucial to combat global public health threats.
New prescriptions for stimulants among adults with ADHD more than doubled since the COVID-19 pandemic, with the largest increases among younger adults. The trend is driven by improved recognition and treatment of ADHD in adulthood, as well as increased access to care and virtual health services.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new medication called zorevunersen has been found to reduce seizures in children with Dravet syndrome by up to 91%, improving their quality of life and behavior. The study, led by University College London and Great Ormond Street Hospital, also showed the potential to reduce the impact of the condition on mental processes.
Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.
The study found that opioids provide only small, time-limited pain relief for certain pain conditions, such as stomach pain and dental surgery. Regular use of opioids comes with a risk of harm, including dependence and overdose.
A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...
A study by São Paulo State University found that an iron-based compound eliminated lung infection in mice after 30 days of treatment. The researchers developed lipid nanoparticles to improve stability and duration of action, outperforming standard antibiotics in eliminating the bacterial load.
A study published in JAMA Network Open found that early hydrocortisone treatment increases the chance of surviving without lung disease for extremely premature babies. The treatment is safe and does not increase serious side effects.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
Researchers at the University of Iowa Health Care identified acetazolamide as a potential target for preventing opioid use disorder relapse. The study found that blocking the activity of brain enzyme carbonic anhydrase 4 boosted acid-sensing ion channels, reducing drug-seeking behavior and relapse in mice.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Researchers found that brexpiprazole significantly improved information processing speed without worsening psychiatric symptoms in patients with schizophrenia. Cognitive dysfunction is a persistent challenge, affecting daily functioning and social participation.
Researchers discovered that collaborative care programs improve quality of life, reduce costs, and alleviate caregiver burden for dementia patients. Adding lecanemab to treatment increased healthcare costs but was offset by the savings from collaborative care.
A new study found semaglutide to be an effective treatment for preventing secondary cardiovascular disease in US adults. The medication meets conventional thresholds when used alone, but its cost-effectiveness is improved with combination therapy.
A new study offers hope that kidney transplant patients may one day have a more effective treatment regimen. The Phase 2 pilot study showed improved kidney functioning in all patients who completed the study, with no patients experiencing rejection due to antibodies produced by the immune system.